Related Experiment Video
Updated: Feb 20, 2026
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years
1Center for Interstitial Lung Diseases, University of Washington, Seattle, WA, USA graghu@uw.edu.
Abstract:
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease. A major breakthrough in treatment came when, after decades of clinical trials which failed to identify an efficacious treatment regimen, two therapies were successful in Phase-III trials. The advent of these therapies, nintedanib and pirfenidone, meant that for the first time IPF patients had two treatment options that could reduce disease progression. This review summarises the key lessons to be obtained from the clinical trials that led to the current international clinical practice guidelines for the treatment of IPF and provides insights for the design of future clinical trials that are needed if we are to improve outcomes that are clinically meaningful to IPF patients.
Insights
Idiopathic pulmonary fibrosis (IPF) treatment has advanced with nintedanib and pirfenidone, offering new options. This review analyzes past trials to guide future research for better patient outcomes.
Area of Science:
- Pulmonology
- Clinical Trials
- Pharmacology
Background:
- Idiopathic pulmonary fibrosis (IPF) is a fatal, progressive lung disease.
- Historically, effective treatments for IPF were lacking.
- Recent advancements include two Phase-III trial-proven therapies: nintedanib and pirfenidone.
Purpose of the Study:
- To review key lessons from clinical trials informing current IPF treatment guidelines.
- To provide insights for designing future IPF clinical trials.
- To improve clinically meaningful outcomes for IPF patients.
Main Methods:
- Review of pivotal Phase-III clinical trials for nintedanib and pirfenidone.
- Analysis of trial data informing international clinical practice guidelines for IPF.
- Synthesis of findings to propose future research directions.
Main Results:
- Nintedanib and pirfenidone represent a significant breakthrough in IPF management.
- These therapies are the first to demonstrate a reduction in IPF disease progression.
- Clinical trials have established the foundation for current international treatment guidelines.
Conclusions:
- The advent of nintedanib and pirfenidone has transformed IPF treatment possibilities.
- Lessons learned from past trials are crucial for optimizing future IPF therapeutic development.
- Further research is essential to achieve more significant improvements in patient outcomes for IPF.
Related Concept Videos
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History